Potentiating prostate cancer immunotherapy with oncolytic viruses
/in International Publications, Newcastle Disease Virus, Prostate Cancer /von 2018-02-13 / Nat Rev Urol 2018 Apr;15(4):235-250Myeloid and plasmacytoid dendritic cell vaccinations for castration-resistant prostate cancer patients.
/in Dendritic Cells, International Publications, Prostate Cancer /von 2018-02-08 / J Clin Oncol 36, 2018 (suppl 6S; abstr 219)Genetically engineered oncolytic Newcastle disease virus mediates cytolysis of prostate cancer stem like cells
/in International Publications, Newcastle Disease Virus, Prostate Cancer /von 2017-09-19 / J. Biotechnol. 2017 Oct;260:91-97Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Newcastle Disease Virus, Prostate Cancer /von 2017-09-01 / G Chir 2017 Sep-Oct;37(5):225-235Current status of clinical trials assessing oncolytic virus therapy for urological cancers
/in Hypernephroma, International Publications, Newcastle Disease Virus, Prostate Cancer, Urothelial Carcinoma /von 2017-03-21 / Int. J. Urol. 2017 05;24(5):342-351A comprehensive review of immunotherapies in prostate cancer
/in Dendritic Cells, International Publications, Newcastle Disease Virus, Prostate Cancer /von 2017-03-02 / Crit. Rev. Oncol. Hematol. 2017 May;113:292-303Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study
/in Dendritic Cells, International Publications, Prostate Cancer /von 2017-02-15 / Cytotherapy 2017 04;19(4):500-513Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients
/in Dendritic Cells, International Publications, Prostate Cancer /von 2017-01-10 / Clin. Cancer Res. 2017 07;23(13):3352-3364The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
/in Dendritic Cells, International Publications, Prostate Cancer /von 2016-12-20 / J Immunother Cancer 2016;4:92
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de